Partial inhibition of aldose reductase by nitazoxanide and its molecular basis.
Zheng, X., Zhang, L., Chen, W., Chen, Y., Xie, W., Hu, X.(2012) ChemMedChem 7: 1921-1923
- PubMed: 22890894 
- DOI: https://doi.org/10.1002/cmdc.201200333
- Primary Citation of Related Structures:  
3V35, 3V36 - PubMed Abstract: 
A little is more than enough: Aldose reductase (AR) is a potential target in a wide range of diseases but its utility may be limited by the side effects caused by complete inhibition. Furthermore, known inhibitors of AR have suffered in clinical evaluation due to poor bioavailability. Here, the clinically used antiprotozoal drug nitazoxanide with proven bioavailability has been shown to partially inhibit AR, potentially circumventing the negatives effects of complete enzyme inhibition.
Organizational Affiliation: 
School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006 (China).